HK1040920B - 緩釋藥物組合物和釋放藥學活性試劑的方法 - Google Patents

緩釋藥物組合物和釋放藥學活性試劑的方法

Info

Publication number
HK1040920B
HK1040920B HK02102698.9A HK02102698A HK1040920B HK 1040920 B HK1040920 B HK 1040920B HK 02102698 A HK02102698 A HK 02102698A HK 1040920 B HK1040920 B HK 1040920B
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
active agent
sustained release
pharmaceutically active
release pharmaceutical
Prior art date
Application number
HK02102698.9A
Other languages
English (en)
Other versions
HK1040920A1 (en
Inventor
R‧沙赫
A‧P‧帕特爾
R‧T‧薩德瑞
Original Assignee
諾瓦提斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1040920(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 諾瓦提斯公司 filed Critical 諾瓦提斯公司
Publication of HK1040920A1 publication Critical patent/HK1040920A1/xx
Publication of HK1040920B publication Critical patent/HK1040920B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02102698.9A 1998-10-14 2002-04-10 緩釋藥物組合物和釋放藥學活性試劑的方法 HK1040920B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (2)

Publication Number Publication Date
HK1040920A1 HK1040920A1 (en) 2002-06-28
HK1040920B true HK1040920B (zh) 2005-07-29

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102698.9A HK1040920B (zh) 1998-10-14 2002-04-10 緩釋藥物組合物和釋放藥學活性試劑的方法

Country Status (30)

Country Link
EP (1) EP1121116B1 (zh)
JP (2) JP2002527388A (zh)
KR (1) KR100517090B1 (zh)
CN (1) CN1196481C (zh)
AR (2) AR020780A1 (zh)
AT (1) ATE382345T1 (zh)
AU (1) AU765475B2 (zh)
BR (1) BR9911648A (zh)
CA (1) CA2346868C (zh)
CO (1) CO5140079A1 (zh)
CY (1) CY1107874T1 (zh)
DE (1) DE69937891T2 (zh)
DK (1) DK1121116T3 (zh)
ES (1) ES2297936T3 (zh)
HK (1) HK1040920B (zh)
HU (1) HUP0104268A3 (zh)
ID (1) ID29350A (zh)
IL (2) IL142375A0 (zh)
MY (1) MY121105A (zh)
NO (1) NO327285B1 (zh)
NZ (1) NZ511010A (zh)
PE (1) PE20001110A1 (zh)
PL (1) PL198850B1 (zh)
PT (1) PT1121116E (zh)
RU (1) RU2259826C2 (zh)
SK (2) SK286595B6 (zh)
TR (1) TR200101088T2 (zh)
TW (1) TW577738B (zh)
WO (1) WO2000021525A2 (zh)
ZA (1) ZA200103001B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093859A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
DZ3473A1 (fr) * 2000-09-29 2002-04-04 Solvay Pharm Bv Formulation pharmaceutique a liberation prolongee independante de la force ionique.
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2004024184A1 (ja) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
US20070042143A1 (en) 2003-04-23 2007-02-22 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
MX2008010879A (es) * 2006-02-24 2008-10-27 Teva Pharma Composiciones farmaceuticas de sodio de fluvastatina.
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
SG11201505352RA (en) * 2013-01-09 2015-08-28 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USE
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
UA29513C2 (uk) * 1995-12-22 2000-11-15 Кова Компані, Лтд Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
ID29350A (id) 2001-08-23
CA2346868C (en) 2008-09-09
SK286596B6 (sk) 2009-01-07
JP2002527388A (ja) 2002-08-27
MY121105A (en) 2005-12-30
IL142375A (en) 2012-01-31
AU6090999A (en) 2000-05-01
IL142375A0 (en) 2002-03-10
PE20001110A1 (es) 2000-11-01
KR20010080156A (ko) 2001-08-22
CY1107874T1 (el) 2013-06-19
HUP0104268A2 (hu) 2002-04-29
SK286595B6 (sk) 2009-01-07
NO20011695D0 (no) 2001-04-04
RU2259826C2 (ru) 2005-09-10
NZ511010A (en) 2003-10-31
AR069281A2 (es) 2010-01-13
ZA200103001B (en) 2002-07-11
CO5140079A1 (es) 2002-03-22
AR020780A1 (es) 2002-05-29
HUP0104268A3 (en) 2002-06-28
ATE382345T1 (de) 2008-01-15
EP1121116B1 (en) 2008-01-02
DE69937891T2 (de) 2008-12-11
CN1328454A (zh) 2001-12-26
AU765475B2 (en) 2003-09-18
WO2000021525A2 (en) 2000-04-20
SK5092001A3 (en) 2001-09-11
PL198850B1 (pl) 2008-07-31
PL348109A1 (en) 2002-05-06
PT1121116E (pt) 2008-03-12
EP1121116A2 (en) 2001-08-08
KR100517090B1 (ko) 2005-09-27
WO2000021525A3 (en) 2000-08-10
BR9911648A (pt) 2001-03-20
HK1040920A1 (en) 2002-06-28
NO20011695L (no) 2001-05-30
TW577738B (en) 2004-03-01
ES2297936T3 (es) 2008-05-01
JP4938383B2 (ja) 2012-05-23
JP2006298945A (ja) 2006-11-02
CN1196481C (zh) 2005-04-13
DE69937891D1 (de) 2008-02-14
CA2346868A1 (en) 2000-04-20
NO327285B1 (no) 2009-06-02
TR200101088T2 (tr) 2001-10-22
DK1121116T3 (da) 2008-05-13

Similar Documents

Publication Publication Date Title
PL348109A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
EP1286662A4 (en) TABLETS AND METHODS FOR MODIFIED RELEASE OF HYDROPHILIC AGENTS OR OTHER AGENTS
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
IL148168A0 (en) Pharmaceutical composition of nateglinide and another antidiabetic agent
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
HUP0104303A3 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1337249A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
IL141155A0 (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
EP1117357A4 (en) METHODS AND DEVICES FOR IMPROVING THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
EP1171117A4 (en) LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
PL336296A1 (en) Composition of retarded active substance release and method of obtaining them
PL337867A1 (en) Oral preparation of controllable opioidic analgesic agent release
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
HUP0202654A3 (en) Pharmaceutical compositions of fibrinolytic agent and process for preparation thereof
PL344564A1 (en) Matrix tablet enabling prolonged release of trimethiazidine after oral administration and method of making such tablet
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
EP1154997A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
PL339349A1 (en) Therapeutic agent preparation of controllable active substance release
IL139512A0 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates
PL337868A1 (en) Oral preparation of controllable analgesic agent release
IL126892A0 (en) Pharmaceutical compositions for the sustained release of insoluble active principles
EP1033974A4 (en) ORAL ADMINISTRATIVE FORMS HAVING HIGH ACTIVE SUBSTANCE AND IMMEDIATE AND CHANGED ACTIVE RELEASE AND PROCESS FOR THEIR PREPARATION
GB9904485D0 (en) Method for protecting and/or controlled release of active ingredient
PL350054A1 (en) Sustained release salts of pharmaceutically active peptides and their production

Legal Events

Date Code Title Description
PE Patent expired